# Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

> **NCT00820170** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dasatinib and Paclitaxel

## Key facts

- **NCT ID:** NCT00820170
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820170, "Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00820170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*